Literature DB >> 35570262

Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders.

Govinda Shivaji Jadhav1, Tejas Girish Agnihotri2, Bichismita Sahu1, Aakanchha Jain3.   

Abstract

The global burden of neurological disorders has been increasing day by day which calls for immediate attention to the solutions. Novel drug delivery systems are one of the alternatives that we count on to counteract these disorders. As the blood-brain barrier creates a significant hindrance to the delivery of drugs across the endothelium lining of the brain, nose-to-brain delivery has been the favorite option to administer such drugs. In recent times, bioconjugation has been viewed as a rapidly growing area in the field of pharmaceuticals. The pharmaceutical industry and academic research are investing significantly in bioconjugated structures as an attractive and advantageous potential aid to nanoparticulate delivery systems, with all of its flexible benefits in terms of tailor grafting and custom design as well as overcoming the majority of their drawbacks. This review discusses drug delivery via the intranasal route and gives insight into bioconjugation systems for drug molecules, their chemistry, and benefits over other systems. Conjugation of drugs/macromolecules with peptides, carbohydrates, ligands, and nucleic acids has also been discussed in detail. The figure represents few types of novel drug delivery systems and molecules that have been attempted by researchers for nose-to-brain delivery through nasal (mucosal) route for the effective management of epilepsy, Alzheimer's disease, brain cancer, and other brain disorders.
© 2022. Controlled Release Society.

Entities:  

Keywords:  Antibody conjugates; Bioconjugation strategies; Imaging; Nanoparticles (NPs); Nose-to-brain delivery; Theranostics applications

Year:  2022        PMID: 35570262     DOI: 10.1007/s13346-022-01173-y

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  52 in total

1.  Optimizing antibody immobilization strategies for the construction of protein microarrays.

Authors:  Paul Peluso; David S Wilson; Duc Do; Huu Tran; Maanasa Venkatasubbaiah; David Quincy; Bettina Heidecker; Kelli Poindexter; Neil Tolani; Michael Phelan; Krista Witte; Linda S Jung; Peter Wagner; Steffen Nock
Journal:  Anal Biochem       Date:  2003-01-15       Impact factor: 3.365

2.  Enzymatic activity on a chip: the critical role of protein orientation.

Authors:  Taewoon Cha; Athena Guo; Xiao-Yang Zhu
Journal:  Proteomics       Date:  2005-02       Impact factor: 3.984

Review 3.  Quantitative analysis of drug delivery to the brain via nasal route.

Authors:  Luba Kozlovskaya; Mohammed Abou-Kaoud; David Stepensky
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

4.  Investigation and Demonstration of Catalyst/Initiator-Driven Selectivity in Thiol-Michael Reactions.

Authors:  Stephen H Frayne; Raghavendra R Murthy; Brian H Northrop
Journal:  J Org Chem       Date:  2017-07-25       Impact factor: 4.354

5.  GLUT1 -mediated venlafaxine-thiamine disulfide system-glucose conjugates with "lock-in" function for central nervous system delivery.

Authors:  Yi Zhao; Li Zhang; Yao Peng; Qiming Yue; Li Hai; Li Guo; Qiantao Wang; Yong Wu
Journal:  Chem Biol Drug Des       Date:  2017-11-11       Impact factor: 2.817

6.  Characterization of protein immobilization at silver surfaces by near edge X-ray absorption fine structure spectroscopy.

Authors:  Xiaosong Liu; Chang-Hyun Jang; Fan Zheng; Astrid Jürgensen; J D Denlinger; Kimberly A Dickson; Ronald T Raines; Nicholas L Abbott; F J Himpsel
Journal:  Langmuir       Date:  2006-08-29       Impact factor: 3.882

Review 7.  The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.

Authors:  Per G Djupesland; John C Messina; Ramy A Mahmoud
Journal:  Ther Deliv       Date:  2014-06

Review 8.  Tethering: fragment-based drug discovery.

Authors:  Daniel A Erlanson; James A Wells; Andrew C Braisted
Journal:  Annu Rev Biophys Biomol Struct       Date:  2004

9.  Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.

Authors:  Liang Zou; Xiaowei Liu; Jingjing Li; Wei Li; Lele Zhang; Chaomei Fu; Jinming Zhang; Zhongwei Gu
Journal:  Theranostics       Date:  2021-02-20       Impact factor: 11.556

Review 10.  Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Authors:  Rotimi Sheyi; Beatriz G de la Torre; Fernando Albericio
Journal:  Pharmaceutics       Date:  2022-02-11       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.